Trial
NCT02438995
Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Northwell Health
Collaborators
—
Condition
Carcinoma, Squamous Cell
Intervention
Intraarterial Cetxuimab (Erbitux)
Why stopped
Low enrollment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-11-03